Clinical trial
A Phase 3 Study of UX003 Recombinant Human Betaglucuronidase (rhGUS) Enzyme…
NCT02230566 · Ultragenyx Pharmaceutical Inc, Industry · Completed
Key facts
| NCT number | NCT02230566 |
|---|---|
| Title | A Phase 3 Study of UX003 Recombinant Human Betaglucuronidase (rhGUS) Enzyme Replacement Therapy in Patients With Mucopolysaccharidosis Type 7 (MPS 7) |
| Official title | A Randomized, Placebo-Controlled, Blind-Start, Single-Crossover Phase 3 Study to Assess the Efficacy and Safety of UX003 rhGUS Enzyme Replacement Therapy in Patients With MPS 7 |
| Lead sponsor | Ultragenyx Pharmaceutical Inc, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | MPS 7, Sly Syndrome, Mucopolysaccharidosis, MPS VII |
| Intervention type | Drug, Other |
| Interventions | UX003, Placebo |
| Enrollment | 12 |
| Start date | Dec 1, 2014 |
| Primary completion | May 1, 2016 |
| Completion | May 1, 2016 |
| First posted | Sep 3, 2014 |
| Last update posted | Jul 30, 2020 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: